Iwao Ojima

Last updated
Iwao Ojima
Portrait photo of Dr. Iwao Ojima.jpg
Born (1945-06-05) June 5, 1945 (age 78)
Education University of Tokyo (B.S., M.S., Ph.D.)
AwardsACS Ernest Guenther Award (2019)

ACS Award for Creative Work in Fluorine Chemistry (2013) ACS E. B. Hershberg Award (2001) Chemical Society of Japan Award (1998)

ACS

Contents

Arthur C. Cope Scholar Award (1994)
Scientific career
FieldsOrganic and Medicinal Chemistry
Institutions Stony Brook University
Website stonybrook.edu/commcms/ojima_group

Iwao Ojima (born June 5, 1945, in Japan) is a Japanese-American chemist and university distinguished professor at the State University of New York at Stony Brook (Stony Brook University). [1] He has been widely recognized for his seminal contributions to a range of chemical research at the multifaceted interfaces of chemical synthesis and life sciences. As rare accomplishments, he has received four National Awards from the American Chemical Society in four different fields of research. He is also serving as the director of the Institute of Chemical Biology and Drug Discovery (ICB&DD), [2] as well as the president of the Stony Brook Chapter of the National Academy of Inventors.

Biography

Ojima was born in Yokohama, Japan, in 1945 and educated at the University of Tokyo, Japan (B.S. 1968, Ph.D. 1973). [1]  Before coming to the U.S. as an associate professor at the State University of New York at Stony Brook in 1983, he worked at the Sagami Institute of Chemical Research in Japan, first as a research fellow and later as a senior research fellow and group leader of the organometallic chemistry and organic synthesis research group.  At Stony Brook, he quickly climbed the ranks: he was promoted to professor in 1984, leading professor in 1991, and university distinguished professor in 1995. He served as department chair from 1997 to 2003 and has been serving as the founding director of the Institute of Chemical Biology and Drug Discovery (ICB&DD) since 2003, [2] as well as the president of the Stony Brook Chapter of the National Academy of Inventors from 2015. [3] He has been a visiting professor at the Université Claude Bernard Lyon I, Lyon, France (1989), the University of Tokyo, Tokyo, Japan (1996), the Scripps Research Institute, La Jolla, CA (1997), and Université de Paris XI, BIOCIS, Châtenay-Malabry, France (1997). [1] As an extracurricular activity, he has been serving as the president of the Japan Center at Stony Brook since 2004. [4]

Research areas

In Ojima's early research career, he was mainly engaged in homogeneous catalysis of phosphine-Rh complexes, its development as new synthetic processes, as well as their applications to catalytic asymmetric synthesis and organic synthesis. He received a 25th CSJ Award for Young Investigator for his research on "Highly selective syntheses by means of organosilicon compounds – transition metal complex systems" from the Chemical Society of Japan in 1976. Through the 1970-1980s, he established himself as an authoritative scholar in catalytic asymmetric synthesis, editing a book, "Catalytic Asymmetric Synthesis" (Wiley-VCH) in 1993, and also published the second (2000) and third (2010) editions. This book collectively became a very popular reference book with >4,100 citations. [5] He was a prolific researcher in the development of new synthetic methods based on transition-metal catalyzed reactions and investigations into their mechanisms, which includes hydrosilylation, silylformylation, silylcarbocyclizations (SiCaCs, SiCaB, SiCaT), higher order (carbonylative) cycloadditions, hydroformylation, hydrocarbonylations, amidocarbonylations, cyclohydrocarbonylations, and enantioselective processes such as hydrosilylation, hydrogenation, hydroformylation, Michael addition, allylic alkylation/amination/etherification, etc. [6]

Since the late 1970s, Ojima began his work in organofluorine chemistry by exploring the interface of fluorine chemistry and organometallic chemistry/catalysis. His notable achievements include the development of processes for the highly regioselective hydroformylations of fluoro-olefins, synthesis of N-acylfluoroamino acids via hydroformylation-amidocarbonylation of fluoro-olefins, synthesis of a-trifluoromethylacrylic acid via carboxylation, novel ureidocarbonylation, synthesis of optically pure fluoroamino acids via enzymatic kinetic resolution, etc. [7]  It is noteworthy that Ojima's synthesis of trifluoromethyluracil from 2-bromotrifluoropropene became an industrial process by Japan Halon (then, Tosoh F-Tech). Furthermore, this process was successfully applied to the commercial synthesis of trifluridine (trifluorothymidine), an antiherpes antiviral drug, primarily used on the eye topically, such as "Viroptic" by Tokyo Yuki Gosei Kogyo in early 1990s. [7] His pioneering work on optically pure fluoroamino acids and their use in medicinally active compounds, such as enkephalin, captopril and taxol (paclitaxel), brought medicinal and biomedical applications to the scope of fluorine chemistry community. [7] He edited a book, "Fluorine in Medicinal Chemistry and Chemical Biology" (Wiley-Blackwell, > 1,700 citations) in 2009, featuring the basic principles and exemplary applications of fluorine incorporation to biologically relevant compounds and systems. [8]

One of his renowned achievements is the development of the "β-Lactam Synthon Method", [9] [10] which has been applied to the synthesis of α- and β-amino acids, oligopeptides, peptidomimetics, taxanes and taxoids. This method has been successfully applied for the practical synthesis of the Ojima lactam, a key intermediate for the commercial production of paclitaxel (Taxol), one of the most widely used anticancer drug for chemotherapy, through the Ojima-Holton coupling, [11] as well as for the medicinal chemistry and development of new-generation taxoid anticancer agents. [11] One of his second-generation taxoids, "ortataxel", developed from 14-hydroxy-10-deacetylbaccatin III, and licensed to Indena, SpA, Italy, has advanced to the Phase II human clinical trials. The extensive SAR studies performed in his laboratory have led to the development of numerous highly potent novel second- and third-generation taxoids. The third-generation taxoids showed virtually no difference in potency against drug-resistant and drug-sensitive cell lines. Some of the next-generation taxoids also exhibited excellent potency against cancer stem cells. Other highlights include his common pharmacophore proposal for microtubule-stabilizing anticancer agents, identification of the paclitaxel binding site and its bioactive conformation in the β-tubulin based on photoaffinity labeling and computational analyses, identification of unique characteristics of the next-generation taxoids in cancer cell biology and their mechanism of action, and efficacious tumor-targeted drug delivery of highly potent next-generation taxoids. [11] [12]

Currently, Ojima's research program is focused on the drug discovery and development of next-generation anticancer agents and their tumor-targeted drug delivery, [11] [13] antibacterial agents, [14] antifungal agents, [15] and antinociceptive agents, [16] etc. In his research, all relevant chemistry and biological tools, including computer-aided drug design, chemical synthesis, computational biology, chemical biology and cell biology are integrated in close collaborations with structural biologists, computer biologists, cell biologists, oncologists, microbiologist, pharmacologists, anesthesiologists, toxicologists, etc.

As of January 2024, he has published >500 papers and reviews in leading journals, >100 issued patents, edited nine books, and given >135 plenary and invited lectures in international meetings. SciFinder lists >1,000 publications to his credit.

Awards and honors

Related Research Articles

<span class="mw-page-title-main">K. C. Nicolaou</span> Cypriot-American chemist (born 1946)

Kyriacos Costa Nicolaou is a Cypriot-American chemist known for his research in the area of natural products total synthesis. He is currently Harry C. and Olga K. Wiess Professor of Chemistry at Rice University, having previously held academic positions at The Scripps Research Institute/UC San Diego and the University of Pennsylvania.

<span class="mw-page-title-main">Vincamine</span> Chemical compound

Vincamine is a monoterpenoid indole alkaloid found in the leaves of Vinca minor, comprising about 25–65% of its indole alkaloids by weight. It can also be synthesized from related alkaloids.

Dale Lester Boger is an American medicinal and organic chemist and former chair of the Department of Chemistry at The Scripps Research Institute in La Jolla, CA.

<span class="mw-page-title-main">Flufenamic acid</span> Chemical compound

Flufenamic acid (FFA) is a member of the anthranilic acid derivatives class of nonsteroidal anti-inflammatory drugs (NSAIDs). Like other members of the class, it is a cyclooxygenase (COX) inhibitor, preventing the formation of prostaglandins. FFA is known to bind to and reduce the activity of prostaglandin F synthase and activate TRPC6.

<span class="mw-page-title-main">Organocobalt chemistry</span> Chemistry of compounds with a carbon to cobalt bond

Organocobalt chemistry is the chemistry of organometallic compounds containing a carbon to cobalt chemical bond. Organocobalt compounds are involved in several organic reactions and the important biomolecule vitamin B12 has a cobalt-carbon bond. Many organocobalt compounds exhibit useful catalytic properties, the preeminent example being dicobalt octacarbonyl.

In chemical biology and biomolecular engineering, rational design (RD) is an umbrella term which invites the strategy of creating new molecules with a certain functionality, based upon the ability to predict how the molecule's structure will affect its behavior through physical models. This can be done either from scratch or by making calculated variations on a known structure, and usually complements directed evolution.

Melanie Sarah Sanford is an American chemist, currently the Moses Gomberg Distinguished University Professor of Chemistry and Arthur F. Thurnau Professor of Chemistry at the University of Michigan. She is a Fellow for the American Association for the Advancement of Science, and was elected a member of the National Academy of Sciences and the American Academy of Arts and Sciences in 2016. She has served as an executive editor of the Journal of the American Chemical Society since 2021, having been an associate editor of the since 2014.

<span class="mw-page-title-main">DIOP</span> Chemical compound

DIOP is an organophosphorus compound that is used as a chiral ligand in asymmetric catalysis. It is a white solid that is soluble in organic solvents.

Medicinal fungi are fungi that contain metabolites or can be induced to produce metabolites through biotechnology to develop prescription drugs. Compounds successfully developed into drugs or under research include antibiotics, anti-cancer drugs, cholesterol and ergosterol synthesis inhibitors, psychotropic drugs, immunosuppressants and fungicides.

<span class="mw-page-title-main">Robert Vince (scientist)</span> American scientist (born 1940)

Robert Vince is an American scientist known for his contributions to the research in the area of drug design. He is currently the director and professor at the Center for Drug Design at the Academic Health Center for the University of Minnesota.

Future Medicinal Chemistry is a peer-reviewed medical journal covering all aspects of medicinal chemistry, including drug discovery, pharmacology, in silico drug design, structural characterization techniques, ADME-Tox investigations, and science policy, economic and intellectual property issues. It was established in 2009 and is published by Future Science. The editors-in-chief are Iwao Ojima and Jonathan Baell.

<span class="mw-page-title-main">Dennis P. Curran</span>

Dennis P. Curran is an American organic chemist and a professor of chemistry at University of Pittsburgh known for his research in the fields of organic chemistry, radical chemistry, and fluorous chemistry.

Clark Landis is an American chemist, whose research focuses on organic and inorganic chemistry. He is currently a Professor of Chemistry at the University of Wisconsin–Madison. He was awarded the ACS Award in Organometallic Chemistry in 2010, and is a fellow of the American Chemical Society and the American Association for the Advancement of Science.

Mark S. Cushman is an American chemist, whose primary research is in the area of medicinal chemistry. He completed his pre-pharmacy studies at Fresno State College (now California State University, Fresno) in 1965. He then attended the University of California San Francisco (as a University of California Regents Scholar), earning a Pharm.D. in 1969 and a Ph.D. in Medicinal Chemistry in 1973. Thereafter, he performed postdoctoral training in the laboratory of George Büchi, Ph.D., at the Massachusetts Institute of Technology (MIT). There, his research focused on the discovery and development of new synthetic methodologies, and the isolation and structural characterization of mycotoxins from Aspergillus niger. In 1975, he joined the Department of Medicinal Chemistry and Molecular Pharmacology (at the time, Department of Medicinal Chemistry and Pharmacognosy) at Purdue University. From 1983 to 1984, Prof. Cushman was a Senior Fulbright Scholar at Munich Technical University working in the laboratory of Professor Adelbert Bacher. His sabbatical work dealt with the design and synthesis of probes to elucidate key aspects of the biosynthesis of riboflavin (vitamin B2). Currently he holds the rank of Distinguished Professor Emeritus of Medicinal Chemistry at Purdue University. He has mentored 40 graduate students, 59 postdoctoral researchers, and 5 visiting scholars. He has published 348 papers and holds 41 patents. His work has ~17,000 citations with an h-index of 69. His most cited papers had 471, 403, and 299 citations as of August 2021. He has made seminal contributions to the fields of synthetic and medicinal chemistry including the development of new synthetic methodologies, the synthesis of natural products, and the preparation of antivirals, antibacterials, and anticancer agents, and mechanism probes to understand the function of over thirty macromolecular targets. One of his main scientific contributions is the development of the indenoisoquinolines, molecules that inhibit the action of toposiomerase I (Top1) and stabilize the G-quadruplex in the Myc promoter. Three indenoisoquinolines designed and synthesized by his research group at Purdue University [indotecan (LMP 400), indimitecan (LMP 776), and LMP 744] demonstrated potent anticancer activity in vivo and have completed phase I clinical trials at the National Institutes of Health.

Donna M. Huryn is an American medicinal and organic chemist. She received her B.A. (chemistry) from Cornell University, and Ph.D. in organic chemistry from the University of Pennsylvania. She is on the faculty at the University of Pittsburgh’s school of pharmacy, holds an adjunct appointment in the department of chemistry at the University of Pennsylvania, is the principal investigator of the University of Pittsburgh Chemical Diversity Center, and was a visiting fellow in the summer of 2017 at the University of Bologna. She is a fellow of the American Chemical Society, recipient of the ACS Philadelphia Local Section Award, has held a number of elected positions within the American Chemical Society at both the local and national levels, and is 2015 Chair of the Division of Organic Chemistry. Huryn also formed, along with a number of other scientists, the Empowering Women in Organic Chemistry Conferences in 2019. The goal was to empower and bring the research and career of all marginalized individuals in chemistry-related fields to the forefront of the scientific community. Huryn noticed how there was not enough women pursuing and maintaining a career in organic chemistry, and thus founded this organization. The Empowering Women in Organic Chemistry Conferences allowed for women leaders to present their scientific findings and hear the stories of how eminent women in the field of organic chemistry overcame the challenges they faced being female. She is associate editor of ACS Medicinal Chemistry Letters. She in also an editor of the journal Organic Reactions and co-authored the textbook Medicinal Chemistry and the article "Medicinal Chemistry: Where Are All the Women?" which appeared in the ACS Medicinal Chemistry Letters Journal. Huryn’s research focuses on the design and synthesis of small molecules probes and drugs to treat cancer, neurodegenerative and infectious diseases.

<span class="mw-page-title-main">Peter J. H. Scott</span>

Peter J. H. Scott FRSC CChem is a British and American chemist and radiochemist who is a professor of radiology, professor of pharmacology and professor of medicinal chemistry, as well as a core member of the Rogel Cancer Center at the University of Michigan in the United States. He is Chief of Nuclear Medicine and director of the University of Michigan Positron Emission Tomography (PET) Center, and runs a research group developing new radiochemistry methodology and novel PET radiotracers.

Angela Casini is a medicinal and inorganic chemist who works on metal-based compounds as therapeutic agents. She was awarded the 2012 European Medal for Bio-Inorganic Chemistry and made the 2019 American Chemical Society Inorganic Lecturer.

Thomas Lectka is an American organic chemist, academic and researcher. He is Jean and Norman Scowe Professor of Chemistry and leads the Lectka Group at Johns Hopkins University.

Kathlyn Ann Parker is a chemist known for her work on synthesis of compounds, especially organic compounds with biological roles. She is an elected fellow of the American Chemical Society and a recipient of the Garvan–Olin Medal in chemistry.

Professor Stephen Neidle is a British X-ray crystallographer, chemist and drug designer working at the UCL School of Pharmacy. His area of scientific research has been in nucleic acid structure and recognition, and the research topic of quadruplexes.

References

  1. 1 2 3 "Iwao Ojima | Chemistry". www.stonybrook.edu. Retrieved 2019-06-04.
  2. 1 2 "Stony Brook University Welcome to the Institute of Chemical Biology & Drug Discovery". www.stonybrook.edu. Retrieved 2019-06-04.
  3. ↑ "Home | Chapter of the National Academy of Inventors". www.stonybrook.edu. Retrieved 2019-06-04.
  4. ↑ "Home | Japan Center at Stony Brook". www.stonybrook.edu. Retrieved 2019-06-04.
  5. ↑ Ojima, Iwao, ed. (2010-02-10). Catalytic Asymmetric Synthesis. Hoboken, NJ, USA: John Wiley & Sons, Inc. doi:10.1002/9780470584248. ISBN   9780470584248. S2CID   93318061.
  6. ↑ "Publications list of Iwao Ojima" (PDF). Stony Brook University.
  7. 1 2 3 Ojima, Iwao (2013-07-05). "Exploration of Fluorine Chemistry at the Multidisciplinary Interface of Chemistry and Biology". The Journal of Organic Chemistry. 78 (13): 6358–6383. doi:10.1021/jo400301u. ISSN   0022-3263. PMC   3752428 . PMID   23614876.
  8. ↑ Yamazaki, Takashi; Taguchi, Takeo; Ojima, Iwao (2009-04-03), Ojima, Iwao (ed.), "Unique Properties of Fluorine and their Relevance to Medicinal Chemistry and Chemical Biology", Fluorine in Medicinal Chemistry and Chemical Biology, John Wiley & Sons, Ltd, pp. 1–46, doi:10.1002/9781444312096.ch1, ISBN   9781444312096, S2CID   93933024
  9. ↑ Ojima, Iwao (1995). "Recent Advances in the .beta.-Lactam Synthon Method". Accounts of Chemical Research. 28 (9): 383–389. doi:10.1021/ar00057a004. ISSN   0001-4842.
  10. ↑ Ojima, Iwao; Delaloge, Francette (1997). "Asymmetric synthesis of building-blocks for peptides and peptidomimetics by means of the β-lactam synthon method". Chem. Soc. Rev. 26 (5): 377–386. doi:10.1039/CS9972600377. ISSN   0306-0012.
  11. 1 2 3 4 Ojima, Iwao; Wang, Xin; Jing, Yunrong; Wang, Changwei (2018-02-22). "Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery". Journal of Natural Products. 81 (3): 703–721. doi:10.1021/acs.jnatprod.7b01012. ISSN   0163-3864. PMC   5869464 . PMID   29468872.
  12. ↑ Ojima, Iwao (2008). "Guided Molecular Missiles for Tumor-Targeting Chemotherapy—Case Studies Using the Second-Generation Taxoids as Warheads". Accounts of Chemical Research. 41 (1): 108–119. doi:10.1021/ar700093f. ISSN   0001-4842. PMID   17663526.
  13. ↑ Ojima, Iwao (2008-04-15). "ChemInform Abstract: Guided Molecular Missiles for Tumor-Targeting Chemotherapy-Case Studies Using the Second-Generation Taxoids as Warheads". ChemInform. 39 (16). doi:10.1002/chin.200816271. ISSN   0931-7597.
  14. ↑ Kumar, Kunal; Awasthi, Divya; Berger, William T; Tonge, Peter J; Slayden, Richard A; Ojima, Iwao (August 2010). "Discovery of anti-TB agents that target the cell-division protein FtsZ". Future Medicinal Chemistry. 2 (8): 1305–1323. doi:10.4155/fmc.10.220. ISSN   1756-8919. PMC   3039483 . PMID   21339840.
  15. ↑ Lazzarini, Cristina; Haranahalli, Krupanandan; Rieger, Robert; Ananthula, Hari Krishna; Desai, Pankaj B.; Ashbaugh, Alan; Linke, Michael J.; Cushion, Melanie T.; Ruzsicska, Bela (2018-03-05). "Acylhydrazones as Antifungal Agents Targeting the Synthesis of Fungal Sphingolipids". Antimicrobial Agents and Chemotherapy. 62 (5). doi:10.1128/aac.00156-18. ISSN   0066-4804. PMC   5923120 . PMID   29507066.
  16. ↑ Yan, Su; Elmes, Matthew W.; Tong, Simon; Hu, Kongzhen; Awwa, Monaf; Teng, Gary Y.H.; Jing, Yunrong; Freitag, Matthew; Gan, Qianwen (June 2018). "SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteins". European Journal of Medicinal Chemistry. 154: 233–252. doi:10.1016/j.ejmech.2018.04.050. ISSN   0223-5234. PMC   5999033 . PMID   29803996.
  17. ↑ "Arthur C. Cope Scholar Awards". American Chemical Society. Retrieved 2019-05-17.
  18. ↑ "John Simon Guggenheim Foundation | Iwao Ojima" . Retrieved 2019-05-22.
  19. ↑ "Elected Fellows". American Association for the Advancement of Science. Retrieved 2019-05-22.
  20. ↑ "CSJ Awards". www.csj.jp. Retrieved 2019-05-17.
  21. ↑ "www.nyas.org".
  22. ↑ "E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances". American Chemical Society. Retrieved 2019-05-17.
  23. ↑ "2010 ACS Fellows". American Chemical Society. Retrieved 2019-05-23.
  24. ↑ "ACS 2013 National Award Winners". Chemical and Engineering News. 90 (34): 53–54. 20 August 2012.
  25. ↑ "Fellows List - National Academy of Inventors". academyofinventors.org. Archived from the original on 2019-06-21. Retrieved 2019-05-23.
  26. ↑ "2019 National Award Recipients". American Chemical Society. Retrieved 2019-05-06.
  27. ↑ "European Academy of Sciences - Iwao Ojima". www.eurasc.org. Retrieved 2021-01-26.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.